Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann N Y Acad Sci. 2012 Feb;1250:33-40. doi: 10.1111/j.1749-6632.2012.06467.x.

SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models.

Author information

1
David Geffen/UCLA School of Medicine, Department of Pathology and Laboratory Medicine, and Human Genetics, Los Angeles, California 90095-1732, USA. rgatti@mednet.ucla.edu

Abstract

Within less than 10 years after the realization of the double helix of DNA, the ability of aminoglycosides to influence the misreading or readthrough of premature termination codons was discovered. It took another three decades to clone and sequence disease genes and appreciate the similarity of mutation spectra for most inborn errors. Nonsense mutations once again have become the target of readthrough compounds. In this brief review, we trace the development in our laboratory of the next generation of readthrough agents, small molecule readthrough (SMRT) drug-like chemicals, and assays for comparing their in vitro activity. Possible mechanisms of action and potential clinical applications are considered.

PMID:
22364446
PMCID:
PMC3754805
DOI:
10.1111/j.1749-6632.2012.06467.x
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center